Current and future botulinum neurotoxin type A preparations in aesthetics: A literature review

Journal of Drugs in Dermatology

Volumn 9, Issue 9, 2010, Pages 1065-1071

  Sattler, Gerhard ^a  

^a Rosenparkklinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; GANGLIOSIDE; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; ANESTHETIC AGENT; MUSCLE RELAXANT AGENT;

BLEPHAROSPASM; CLOSTRIDIUM BOTULINUM; COMPARATIVE STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSTONIC DISORDER; ECCHYMOSIS; ELECTROMYOGRAPHY; EYE DISEASE; FOLLOW UP; HEADACHE; HEMATOMA; HUMAN; HYPERHIDROSIS; INJECTION SITE REACTION; MIGRAINE; MOLECULAR WEIGHT; MUSCLE SPASM; NEUROLOGIC DISEASE; PAIN; PARALYSIS; PATIENT SATISFACTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRURITUS; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGIDITY; ROSACEA; STRABISMUS; SWELLING; TORTICOLLIS; TREATMENT DURATION; TREATMENT RESPONSE; VERTIGO; WRINKLE; CUTANEOUS PARAMETERS; DRUG COMBINATION; ESTHETIC SURGERY; IMMUNOLOGY;

ANESTHETICS; BOTULINUM TOXIN TYPE A; COSMETIC TECHNIQUES; DRUG COMBINATIONS; HUMANS; NEUROMUSCULAR AGENTS; SKIN AGING;

EID: 77957950946     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Carruthers J, Fagien S, Matarasso SL. Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial esthetics. Plastic Reconstr Surg. 2004;114:1S-22S. (Pubitemid 40354480)
2. Borodic G. Immunologic resistance after repeated botulinum toxin type A injections for facial rhytides. Ophthal Plast Reconstr Surg. 2006;22:239-240. (Pubitemid 44510175)
3. Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: An evidence-based review. Plastic Reconstr Surg. 2008;121:413e-22e.
4. Absar MS, Onwudike M. Efficacy of botulinum toxin type A in the treatment of focal axillary hyperhidrosis. Dermatol Surg. 2008;34:751-755. (Pubitemid 351792285)
5. Dressler D. New formulation of BOTOX®: Complete antibody-induced therapy failure in hemifacial spasm. J Neurol. 2004;251:360. (Pubitemid 38387161)
6. Dressler D. Klinische Relevanz von Botulinum-Toxin-Antikörpern. Nervenarzt. 2008;79(Suppl 1):36-40.
7. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29:1761-1768. (Pubitemid 350176807)
8. Klein A. Complications and adverse reactions with the use of botulinum toxin. Dis Mon. 2002;48:336-356. (Pubitemid 35007059)
9. Jost WH, Blumel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia. Drugs. 2007;67:5:669-683. (Pubitemid 46535642)
10. Jost W. Efficacy and safety of botulinum neurotoxin type A free of complexing proteins (NT 201) in cervical dystonia and blepharospasm. Future Neurol. 2007;2:485-493. (Pubitemid 47455721)
11. Wohlfarth K, Müller C, Sassin I, et al. Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol. 2007;30:86-94. (Pubitemid 46581201)
12. Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX®) in healthy volunteers. J Neural Transm. 2005;112:905-913. (Pubitemid 40869079)
13. Dressler D, Hallett M. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurology. 2006;13(Suppl 1):11-15.
14. Carruthers A, Carruthers J. Botulinum toxin products overview. Skin Ther Letter. 2008;13:1-4.
15. Carruthers J, Glogau R, Blitzer A, et al. Advances in facial rejuvenation: Botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies - Consensus recommendations. Plast Reconstr Surg. 2008;121:5S-30S. (Pubitemid 351674120)
16. Flynn T. An analysis of botulinum toxins. UK J Med Aesthetics and Anti-Aging. 2008;13-16.
17. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46:840-849.
18. Carruthers JD, Lowe NJ, Menter MA, et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112:1089-1098. (Pubitemid 38251807)
19. Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol. 2002;47:834-840. (Pubitemid 35403040)
20. Lowe NJ, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31:57-262.
21. Levy JL, Servant JJ, Jouve E. Botulinum toxin A: A 9-month clinical and 3D in vivo profilometric crow's feet wrinkle formation study. J Cosmet Laser Ther. 2004;6:16-20. (Pubitemid 38661143)
22. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol. 2004;51:223-233. Erratum in: J Am Acad Dermatol. 2005;52:156.
23. Monheit G, Carruthers A, Brandt F, Rand R. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal dose. Dermatol Surg. 2007;33(1 Spec No.):S51-S59.
24. Moy R, Maas C, Monheit G, Huber MB; Reloxin Investigational Group. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg. 2009;11:77-83.
25. Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis results from a national survey. J Am Acad Dermatol. 2004;51:241-248.
26. Rosales RL, Bigalke H, Dressler D. Pharmacology of botulinum toxin: Differences between type A preparations. Eur J Neurol. 2006;13(Suppl 1):2-10.
27. Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport® vs. Botox®in primary palmar hyperhidrosis. Br J Dermatol. 2003;149:1041-1045. (Pubitemid 37541992)
28. Karsai S, Adrian R, Hammes S, et al. A randomized, double-blind study of the effect of Botox® and Dysport®/Reloxin® on forehead wrinkles and electromyographic activity. Arch Derm. 2007;143:1147-1149.
29. Karsai S, Raulin C. Current evidence on the unit equivalence of different botulinum neurotoxin A formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35:1-8.
30. Dayan SH, Maas CS. Botulinum toxins for facial wrinkles: Beyond glabellar lines. Facial Plast Surg Clin North Am. 2007;15:41-49.
31. Carruthers J, Carruthers A. Esthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg. 2003;29:468-476. (Pubitemid 36583143)
32. Wiest LG. An overview of the cosmetics treatment of facial muscles with a new botulinum toxin. Acta Dermatovenerol Croat. 2009;17:48-53.
33. Sommer B, Sattler G. Botulinumtoxin in der ästhetischen Medizen. 3rd edition. Stuttgart: Thieme; 2006.
34. Hambleton P. Clostridium botulinum toxins: A general review of involvement in disease, structure, mode of action and preparation for clinical use. J Neurol. 1992;239:16-20.
35. Eisele K-H, Taylor HV. Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions. Toxicon. 2008;51(Suppl 1):S10.
36. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord. 1994;9:213-217. (Pubitemid 24092341)
37. Müller K, Mix E, Adib Saberi F, et al. Prevalence of neutralizing antibodies in patients treated with botulinum toxin type A for spasticity. J Neural Transm. 2009;116:579-585.
38. Lee S-K. Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg. 2007;33:S105-S110. (Pubitemid 46051408)
39. Xeomin®. Summary of Product Characteristics (Germany), Merz Pharmaceuticals. 2009.
40. Bocouture®. Summary of Product Characteristics (Germany), Merz Pharmaceuticals. 2009.
41. Stenmark P, Dupuy J, Imamura A, et al. Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b: insight into the toxin-neuron interaction. PLoS Pathog. 2008;4(8):e1000129.
42. Eisele KH, Grein S, Mander GJ, Taylor HV. Role of complexing proteins in pharmaceutical botulinum neurotoxin formulations. Poster #733, presented at IMCAS. Paris, France, 2009.
43. Kerscher M, Maack M, Reucher T, Kruger N. Diffusion characteristics of two different neurotoxins in patients with symmetric forehead lines. J Am Acad Dermatol. 2007;56(Suppl 2):2911.
44. Goschel H, Wohlfarth K, Frevert J, et al. Botulinum A toxin therapy: Neutralizing and nonneutralizing antibodies-therapeutic consequences. Experimental Neurol. 1997;147:96-102. (Pubitemid 27402446)
45. Dressler D. Pharmacological aspects of therapeutic botulinum toxin preparations. Nervenarzt. 2006;77:912-921. (Pubitemid 44212148)
46. Blümel J. NT 201 - A new botulinum toxin A preparation free of complexing proteins demonstrating the safety and benefit of decreased total clostridial protein burden. Parkinsonism Rel Disord. 2005;11(Suppl 2):267.
47. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186-1188. (Pubitemid 36418786)
48. Blümel J, Frevert J, Schwaier A. Comparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbit. Neurotox Res. 2006;9(Suppl 2):238.
49. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64:1949-1951. (Pubitemid 40800714)
50. Roggenkämper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303-312. (Pubitemid 43201097)
51. Benecke R, Grafe S, Sassin I, Comes G. Overall clinical efficacy and tolerability of NT 201; Botulinum neurotoxin free from complexing proteins. Mov Disord. 2009;24(Suppl 1):S84.
52. Schleyer V, Berneburg M. Efficacy and safety of botulinum neurotoxin type A (Xeomin®) in the treatment of facial expression frown lines. Kosmetische Medizin. 2008;29:148-151.
53. Fritsch C. Efficacy of the new botulinum toxin (Xeomin®) free of complexing proteins in the therapy of mimical smile lines. Kosmetische Medizin. 2006;27:124-129. (Pubitemid 44696544)
54. Dressler D, Mander G, Fink K. Equivalent potency of Xeomin® and Botox®. Toxicon. 2008;51(Suppl 27):10.
55. Clinical Trials website. Available at http://www.clinicaltrials.gov/ct2/ show/NCT00752297?term=purtox&rank=3. Accessed April 21, 2010.
56. Stone AV, Ma J, Whitlock PW, Koman LA. Effects of Botox® and Neuronox® on muscle force generation in mice. J Orthop Res. 2007;25:1658-1664. (Pubitemid 350293814)
57. Medy-Tox website. Available at www.medy-tox.co.kr. Accessed April 21, 2010.